

Edgar Filing: VistaGen Therapeutics, Inc. - Form 8-K

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Item 8.01

Other Events.

VistaGen Therapeutics, Inc. (the “Company”) today announced that the Japanese Patent Office has issued a Notice of Allowance for a patent related to certain methods of production for AV-101 (L-4-chlorokynurenine), the Company’s oral CNS drug candidate. AV-101 is in Phase 2 clinical development in the United States as an adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to current antidepressants approved by the U.S. Food and Drug Administration. A copy of the Company’s press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01

Financial Statements and Exhibits.

See Exhibit Index.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VistaGen Therapeutics,
Inc.

Date: May 2, 2018 By: /s/ Shawn K.
Singh
Shawn K. Singh
Chief Executive
Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release issued by VistaGen Therapeutics, Inc., dated May 2, 2018